Current Status of Onglyza Generics
No generic version of Onglyza (saxagliptin) is available in the U.S. as of 2024. The brand remains protected by remaining patents and pediatric exclusivity, blocking FDA approval of generics via ANDA Paragraph IV challenges.[1]
Key Patent Expirations
- Primary compound patent (U.S. Patent 6,995,181): Expired January 2025, but other patents extend protection.
- Key formulation patents (e.g., 8,414,921 for tablets): Expire May 2026–2027.
- Pediatric exclusivity adds 6 months to the last patent, pushing final expiry to November 2027.[1][2]
Anticipated Generic Entry
Earliest realistic generic launch is late 2027, after final patent expiry and any litigation resolves. Multiple ANDA filers (including Mylan, Lupin, Aurobindo) face ongoing patent suits from Bristol Myers Squibb/AstraZeneca; settlements could allow earlier entry for some, potentially mid-2026.[1][3]
Why Delays Persist
BMS/AZ has enforced secondary patents on dosing and combinations, leading to Hatch-Waxman litigation. No FDA tentative approvals signal generics yet; 180-day exclusivity for first challengers would follow court wins.[2]
Generic Approvals Elsewhere
Generics launched in Europe (2019) and Canada (2020). U.S. lags due to stronger patent thickets.[1]
Cost Savings for Patients
Brand Onglyza costs $500–$600/month without insurance. Generics could drop prices 80–90%, similar to Januvia patterns.[3]
[1]: DrugPatentWatch.com - Onglyza Patents
[2]: FDA Orange Book - Saxagliptin
[3]: FDA Paragraph IV Patent Challenge Database